HC Wainwright Reiterates “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

HC Wainwright reiterated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Friday morning,Benzinga reports.

60 Degrees Pharmaceuticals Stock Down 3.7 %

60 Degrees Pharmaceuticals stock opened at $1.05 on Friday. 60 Degrees Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $13.20. The stock has a 50-day moving average price of $1.19 and a 200 day moving average price of $0.98. The company has a market capitalization of $2.41 million, a price-to-earnings ratio of -0.10 and a beta of 4.40.

Insider Transactions at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow purchased 35,823 shares of the stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $1.27 per share, with a total value of $45,495.21. Following the completion of the acquisition, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This trade represents a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired 66,372 shares of company stock worth $82,410 over the last 90 days. 10.27% of the stock is currently owned by company insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.